NeuroDerm Bought for $1.1B

08:43 EDT 1 Aug 2017 | Contract Pharma

Mitsubishi Tanabe Pharma Corporation acquires lead Phase III Parkinson’s candidate

Original Article: NeuroDerm Bought for $1.1B


More From BioPortfolio on "NeuroDerm Bought for $1.1B"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...